Reasons for AstraZeneca relocating its base to Cambridge City,
AstraZeneca was founded in Sweden by more than 400 doctors. It is one of the leading and best pharmaceutical companies globally (Ansari & Freiberg, 2017). They provide effective medicine that makes significant changes in the life of patients. the company is backed by a strong research base with extensive manufacturing as well as commercial skills. The company corporate headquarters are located in London, while its research and development headquarters were located in Sweden. AstraZeneca provides drugs and medicine in the following medical areas: central nervous system, cardiovascular, anaesthesia and pain control, and gastrointestinal. When I come to sustainability, the company has some proper priorities such as access to health care by increasing access to health care for the underserved patient population, and environmental sustainability, this is done by promoting environmental stewardship across the product life cycle (Ansari, & Freiberg, 2017).
- Reasons why AstraZeneca chose Cambridge City.
In the United Kingdom (UK), Cambridge is one of the most globally famous City. Cambridge city has a significant history of innovation in the field of science as well as medical research. This rich history in science and medicine could be due to the presence of a world-class university and state-of-the-art science park (Flanagan, & Wilsdon, 2018). The science park was founded by Trinity College sometime back in 1970 and is the oldest park in the United Kingdom. It is the centre of medical research companies such as Mundipharm, company, biopharmaceutical, and biotechnology. AstraZeneca confirmed that its move to Cambridge reflects the company international importance as a centre for biopharmaceutical research and development. Cambridge city gave the company a good advantage to access globally, leading to invaluable scientific expertise. Cambridge provided significant chances for collaborations with old academic research institutions system, better biotechnology companies as well as pre-eminent global hospitals.
Since AstraZeneca already had their biologics division Medimmune in Cambridge, it greatly helped them to come closer to it. This helped to enhance the activities of the company with a lot of ease without unnecessary time wastage as well as their resources. Move their base to Cambridge also promotes their partnership (Flanagan, & Wilsdon, 2018). Since best science does not just happen in isolation, AstraZeneca relocation to Cambridge enhanced partnership with other research institution, combining the great science in improved laboratories with complementary technologies to hasten the discovery as well as delivery of new human life-changing medicines
Bringing together world-class capabilities; New Cambridge site of AstraZeneca brings together small molecule as well as biologics research such as Medimmune biologics division. By coming together can results in great ideas that result in development activities across the company’s main focus areas such as working together to discover and develop novel biologics to treat cancer. This is being worked on by AstraZeneca drug discovery scientists, who are working in togetherness with Microsoft to use a cloud-based simulation tool for a better understanding of cancer (Arfvidsson et al. 2017).
AstraZeneca company chose to relocate its research and development facilities and a global headquarter in the City to create a good relationship with leading research, academic and proper healthcare organizations based in and around Cambridge (Mazzetti et al. 2018). For instance, in the case of academic, it can strongly collaborate with the health research student in best academic institution like the Cambridge University, one of the advanced global university in medicine research. They can also partner with other research institutions basically for health professional’s consultation and benchmarking with a lot of ease, and without much resource’s utilization. By setting its base around Cambridge city, their clinicians and those from other research institution such as biotechnology and biopharmaceuticals companies can exchanges medical development ideas to improve patient’s healthcare globally.
AstraZeneca moving its base to Cambridge where there are numerous research and academic institution helps them get constant skilled and experienced employees who can operate without any supervisions in R&D productivity. The company will get easy time when hiring medical researchers since most of them will particularly come from the research institutions and the fresh graduates from the Cambridge Universities advanced in medical research and development (Flanagan, & Wilsdon, 2018). Hiring experienced and competent would boost the level of operation in their products productions hence increase their sales in the competitive global market setting. Availability of experienced employees especially from research institutions brings less risk in work, therefore, builds a culture that encourages creativity and innovative, a critical mission strategy for pharmaceutical company forward movement and sustainability (Mazzetti, et. al. 2018). This is the primary reason most pharmaceutical companies are aggressively courting millennial talent. Older talent from nearby research centers and academic institution is a multi-skilled and adaptable to the working conditions and requirement at Cambridge city.
On the other hand, Cambridge being famous City known globally, relocation may help boost their brand for best sales. In most situations, people only busy from known City (Mazzetti et al. 2018). Being that Cambridge is globally praised as having the best research medical centres and rich history in science and medicine mainly because of the presence of the world-class university and state-of-the-art science park. It is the center of medical research companies such as Mundipharm, company, biopharmaceutical, and biotechnology. Therefore, AstraZeneca would wish their products to be closely associated with the great City known for medical research innovations and development. This could help boost their sales in the current competitive global market.
- UK Contribution to AstraZeneca global competitiveness,
The United Kingdom provides a conducive business environment for the operation of industries such as AstraZeneca. Working with the willing United Kingdom government, policymakers as well as regulatory bodies. This is to make sure that essential access of the patient to innovative medicine (Arfvidsson et al. 2017). On the other hand, United Kingdom also gains by working with the pharmaceutical company since they ensure that the environment for developing new medicine in the UK remains strong and can retain status centre of medical innovation (Flanagan, & Wilsdon, 2018). The government also gains through reasonable taxation, which can be used to develop other key sectors such as infrastructures such as roads. Better infrastructures can help AstraZeneca smoothly and easily transport their products across the country and other parts of the world. The British Association for Pharmaceutical Industry also ensures that the voice of the company is significant key debate.
Better working condition with NHS. The NHS is the main customer for AstraZeneca medicine in the UK (Arfvidsson et al. 2017). The company interacts with healthcare professionals as part of their sales and marketing work for their products, and it ensures that clinicians have the best access to any information about the AstraZeneca products, hence makes any significant prescribing decisions. Working closely with NHS employees in the UK assists the AstraZeneca company on proper facilitation on decision- making as well as budgetary planning. This is achieved by aligning AstraZeneca business with NHS priorities to support excellent service delivery of patient care (Arfvidsson et al. 2017). The AstraZeneca UK Marketing Company works on a customer-centric approach to enhance more collaboration thorough understanding of the key needs of the healthcare professionals, commissioners as well as patients who frequently use their products.
Joint working with other institutions such as research centres, healthcare’s, biotechnology and biopharmaceutical in the UK. it provides AstraZeneca company with a formal foundation for proper creation, development and implementing innovative healthcare solution to the whole world, not just the United Kingdom alone, which delivers better and appropriate healthcare service for the patients. However, AstraZeneca has been committed to donation, sponsorship and partnership funding with a lot of openness and transparency. In the line of Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and through proper documentation as well as publicly disclose any transfers of any value made directly or indirectly to health professionals and healthcare organizations.
The UK has boosted a network of truly world-class scientists and a better working environment. The UK has enabled science research companies like AstraZeneca to invest freely, and its scientific research is developing to become one of the key growth sectors. The development and investment in medical research, a strategic sector can underpin economic growth, as well as sustain the UK life science ecosystem (Ledford, 2016). So, the UK government has ultimately strengthened the AstraZeneca global competitiveness through the development of UK Life Science Strategy and some fair and meaningful UK government policies primarily to encourage investments such as that of AstraZeneca company. Similarly, government achievement is to make the UK an attractive location for biopharmaceuticals research and development. And on the other hand, offer AstraZeneca pharmaceutical company a fair competition in the global competitive market setting.
In the UK, AstraZeneca has been the primary beneficiary of science- focused collaborations, mergers, as well as an acquisition for many years (Arfvidsson et al. 2017). This science-focused collaborations in the UK help the professionals in the company to learn and get new ideas from other renowned centres for life science innovations, and bioscience, science talents and ecosystem of world-leading academic research institutions (Ledford, 2016). The healthy ideas gained from the named science research institutions can be converted to better development of new advanced medicinal product globally to compete with other pharmaceuticals companies in the whole world. However, AstraZeneca has also contributed to the UK development through active collaboration with UK academic institutions and students’ programs, and important collaborations with UK NGOs, charities and UK based biotechnology sectors. For instance, AstraZeneca collaborated with the University of Manchester and created Manchester Collaborative Center Inflammation Research to establish a translational research centre for Inflammatory disease in the UK (Ledford, 2016).
References,
Flanagan, K., & Wilsdon, J. (2018). A powerhouse of science? Prospects and pitfalls of place-based science and innovation policies in northern England. In Developing England’s North(pp. 121-138). Palgrave Macmillan, Cham.
Ansari, A., & Freiberg, E. (2017). Supporting Strategic Decisions for Operational Changes through the use of Discrete Event Simulation: A Case Study in Production Scheduling at AstraZeneca.
Ledford, H. (2016). AstraZeneca launches project to sequence 2 million genomes. Nature News, 532(7600), 427.
Fuller, N., Spadola, L., Cowen, S., Patel, J., Schönherr, H., Cao, Q., … & Goodnow, R. (2016). An improved model for fragment-based lead generation at AstraZeneca. Drug Discovery Today, 21(8), 1272-1283.
Arvidsson, C., Severin, P., Holmes, V., Mitchell, R., Bailey, C., Cape, S., … & Harter, T. (2017). AstraZeneca and Covance laboratories clinical bioanalysis alliance: an evolutionary outsourcing model. Bioanalysis, 9(15), 1181-1194
Mervin, L. H., Bulusu, K. C., Kalash, L., Afzal, A. M., Svensson, F., Firth, M. A., … & Bender, A. (2018). Orthologue chemical space and its influence on target prediction. Bioinformatics, 34(1), 72-79.
Mazzetti, M., Hedwall, M., Crowther, M., Lennard, S., Richardson, M., & Taylor, L. (2018, January). AstraZeneca Creates a Culture of Agility and Innovation. Project Management Institute.
Viña, G., Skelding, R., Einhorn, R., Kent, M., Hurst, J., Hägerstrand, C. M., … & Stone, N. (2019). AstraZeneca PLC (AZN). Update, 7, 00.
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., … & Matcham, J. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature reviews Drug discovery, 17(3), 167.
Ansari, A., & Freiberg, E. (2017). Supporting Strategic Decisions for Operational Changes through the use of Discrete Event Simulation: A Case Study in Production Scheduling at AstraZeneca.